Duol Industry Changes Name to ‘OncoQuest Pharmaceuticals’... Restructures Business to Focus on Bio Sector
[Asia Economy Reporter Eunmo Koo] Duol Industry is changing its name to OncoQuest Pharmaceuticals and reorganizing its business to focus on the bio sector.
Duol Industry announced on the 8th that it plans to change its name to OncoQuest Pharmaceuticals at the shareholders' meeting scheduled for the 22nd and appoint new executives. Madiyalakan, CEO of OncoQuest, and Mark Libonan, former director of Quest Pharmatech, will be appointed as inside directors, while Jonathan Berick, professor at Stanford University School of Medicine, and Michael Hollingsworth, professor at the University of Nebraska Medical Center Cancer Research Institute, will be appointed as outside directors.
According to the company, these individuals are global authorities related to the development of ovarian cancer, pancreatic cancer, and breast cancer treatments, which are major pipelines recently secured through asset acquisition. They will serve as advisors for future clinical progress and also participate in company management.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
A Duol Industry official stated, "Following the acquisition of intangible assets including patents, intellectual property rights, and major contracts of OncoQuest through asset acquisition, the bio business is expected to be fully launched by changing the company name and recruiting bio experts as executives through this shareholders' meeting."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
